LA
CVS icon

Lynch & Associates’s CVS Health CVS Stock Holding History

Lynch & Associates’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.44M Buy
28,426
+477
+2% +$46.7K 0.35% 67
2026
Q2 		$2.89M Buy
27,949
+731
+3% +$65.3K 0.51% 52
2026
Q1 		$1.95M Sell
27,218
-62
-0.2% -$4.78K 0.37% 65
2025
Q4 		$2.16M Buy
27,280
+2,467
+10% +$194K 0.41% 57
2025
Q3 		$1.87M Buy
24,813
+1,935
+8% +$133K 0.36% 61
2025
Q2 		$1.58M Buy
22,878
+2,996
+15% +$196K 0.32% 67
2025
Q1 		$1.35M Buy
19,882
+75
+0.4% +$4.49K 0.29% 72
2024
Q4 		$889K Sell
19,807
-6,088
-24% -$342K 0.19% 75
2024
Q3 		$1.63M Sell
25,895
-1,826
-7% -$107K 0.34% 65
2024
Q2 		$1.64M Sell
27,721
-1,605
-5% -$100K 0.37% 61
2024
Q1 		$2.34M Sell
29,326
-571
-2% -$43.6K 0.54% 52
2023
Q4 		$2.36M Sell
29,897
-1,059
-3% -$75.4K 0.57% 50
2023
Q3 		$2.16M Sell
30,956
-3,260
-10% -$231K 0.57% 48
2023
Q2 		$2.37M Sell
34,216
-7,248
-17% -$516K 0.61% 47
2023
Q1 		$3.08M Sell
41,464
-4,246
-9% -$356K 0.81% 42
2022
Q4 		$4.26M Sell
45,710
-575
-1% -$55.5K 1.11% 31
2022
Q3 		$4.41M Buy
46,285
+5,215
+13% +$516K 1.29% 28
2022
Q2 		$3.81M Buy
41,070
+384
+0.9% +$37.5K 1.04% 33
2022
Q1 		$4.12M Buy
40,686
+556
+1% +$58.4K 1% 35
2021
Q4 		$4.14M Buy
40,130
+4,003
+11% +$370K 0.98% 36
2021
Q3 		$3.07M Buy
36,127
+2,031
+6% +$170K 0.79% 41
2021
Q2 		$2.84M Buy
34,096
+9,922
+41% +$813K 0.73% 44
2021
Q1 		$1.82M Buy
24,174
+4,931
+26% +$359K 0.49% 52
2020
Q4 		$1.31M Buy
19,243
+1,892
+11% +$123K 0.36% 58
2020
Q3 		$1.01M Buy
17,351
+1,255
+8% +$78.1K 0.3% 61
2020
Q2 		$1.05M Buy
16,096
+5,230
+48% +$329K 0.34% 56
2020
Q1 		$645K Sell
10,866
-143
-1% -$9.5K 0.24% 65
2019
Q4 		$818K Buy
11,009
+317
+3% +$22.3K 0.24% 65
2019
Q3 		$674K Buy
10,692
+1,272
+14% +$75.4K 0.21% 67
2019
Q2 		$513K Buy
+9,420
New +$507K 0.17% 73

Other funds holding CVS

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return
Canoe Financial
Canoe Financial Calgary, Alberta, Canada $8.31B AUM 20.77% 1-Year Est. Return
Hamlin Capital Management
Hamlin Capital Management New York $4.04B AUM 11.59% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return
Fort Washington Investment Advisors
Fort Washington Investment Advisors Cincinnati, Ohio $19.7B AUM 20.11% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
BI Asset Management Fondsmaeglerselskab
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $13.1B AUM 35.37% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Lynch & Associates's CVS Position: Q3 2026 in Review

Lynch & Associates increased its CVS Health (CVS) stake by 1.7% in Q3 2026, buying an estimated $46.7K and bringing the position to 28,426 shares worth $2.44M. The position accounts for 0.35% of the portfolio, ranked #67.

Lynch & Associates first reported a position in CVS in Q2 2019 and has held it in 30 quarters since. The position peaked at $4.41M in Q3 2022. 542 funds tracked by Wall St. Rank hold CVS as of Q3 2026.

  • Lynch & Associates held 28,426 shares of CVS Health worth $2.44M as of Q3 2026.
  • Lynch & Associates bought 477 CVS Health shares in Q3 2026, an estimated $46.7K.
  • CVS Health made up 0.35% of Lynch & Associates's portfolio in Q3 2026, its #67 holding.
  • Lynch & Associates first reported a position in CVS Health in Q2 2019 and has held it in 30 quarters since.
  • Lynch & Associates's CVS Health position peaked at $4.41M in Q3 2022.
  • 542 funds tracked by Wall St. Rank held CVS Health as of Q3 2026.

Based on Lynch & Associates's 13F filing for Q3 2026, filed 13 Oct 2026.